Shilpa Targets India and EU Albumin Phase III Trials in 2HFY27

Shilpa Medicare plans to initiate Phase III recombinant human albumin trials in India and the European Union in the second half of financial year 2027, after more than eight years of development, while Orion Corporation holds exclusive European commercialization rights for therapeutic use and Shilpa has established a large-scale fermentation facility.

What is Shilpa’s recombinant human albumin?

Shilpa’s recombinant human albumin, or rHA, is produced by fermenting the yeast Pichia pastoris rather than sourcing albumin from plasma. Shilpa says all raw materials used in the manufacturing process are free from animal sources. The company positions rHA as a product intended to address growing demand for human serum albumin, with Phase III trials targeted for India and the European Union in 2HFY27.

Shilpa lists five product attributes: predictable supply, freedom from potential contamination sources, animal-origin-free raw materials, productivity intended to support competitiveness with plasma albumin, and quality and purity intended to meet global standards. It specifically says the process is inherently free from human immunodeficiency virus, hepatitis B virus, hepatitis C virus and prion contamination. These are Shilpa’s manufacturing and product-positioning statements, not disclosed clinical-trial findings.

The difference from plasma albumin is the stated production mechanism. Shilpa uses yeast fermentation and says it has set up a large-scale fermentation facility after investing in the rHA programme for over eight years. The presentation does not disclose fermentation capacity, production yield, manufacturing cost, price or comparative market share, so the claimed productivity comparison with plasma albumin cannot be quantified from the source.

What does Orion’s agreement with Shilpa cover?

Orion is Shilpa’s exclusive partner for the distribution, marketing and sales of therapeutic rHA in Europe. The strategic partnership covers commercialization in the European region, while Shilpa remains entitled to certain development and regulatory milestone payments under the agreement. The source does not give values, payment dates, royalty rates, supply prices or minimum purchase commitments.

The agreement concerns Europe and therapeutic use, which is distinct from Shilpa’s disclosed non-therapeutic activity in the United States. Shilpa says it has shared non-therapeutic rHA samples with United States clients, but it does not identify those clients or state a commercial contract, order value or launch timetable. The company’s therapeutic development plan instead identifies India and the European Union for Phase III initiation in 2HFY27.

Orion’s disclosed role is commercial rather than clinical. Shilpa does not state that Orion will run the Phase III studies, submit regulatory filings or manufacture rHA. The presentation places European commercialization alongside the planned European Union clinical programme, meaning the stated partnership structure is in place before any disclosed therapeutic approval or sales launch.

When will Shilpa start rHA trials and filings?

Shilpa targets Phase III initiation for therapeutic rHA in both India and the European Union in 2HFY27, while planning to file a pre-Investigational New Drug application in the United States during FY27. The company separately says that its global Phase III protocol has been approved by India’s Central Drugs Standard Control Organisation and that it is advancing an international pivotal trial.

India and the European Union are therefore at the same planned Phase III starting point, whereas the United States therapeutic programme is at an earlier disclosed filing stage. The non-therapeutic United States activity is also separate from the therapeutic programme because it involves client samples rather than a Phase III study, regulatory filing or announced commercialization agreement.

Shilpa also targets submission of an Investigational Medicinal Product Dossier to the European Medicines Agency in 2HFY27. The presentation does not provide patient numbers, trial sites, endpoints, dosing, study-completion dates, marketing-application dates or launch timing. Those items remain undisclosed beyond the 2HFY27 trial and filing targets.

How are Shilpa’s patents and manufacturing positioned?

Shilpa says its rHA production technology is covered by patents in the United States and Europe. It presents this patent position alongside more than eight years of development investment and its large-scale fermentation facility. The source does not provide patent numbers, expiry dates, protected claims, licensing terms or any litigation information.

The manufacturing platform is central to Shilpa’s stated product proposition because rHA is made through Pichia pastoris fermentation using animal-origin-free raw materials. Shilpa says this process supports a predictable and assured supply and avoids the listed potential contamination sources associated with plasma-derived material. It does not provide a quantitative comparison of rHA supply volumes or quality measures against plasma albumin.

Shilpa’s adjacent biologics disclosure describes an integrated contract development and manufacturing organisation platform at Dharwad, five active novel biologic entity programmes and three biologics contract development programmes with Phase I clinical supplies. For rHA, however, the specific disclosures are the dedicated large-scale fermentation facility, patents in the United States and Europe, and the planned India and European Union Phase III work in 2HFY27.

Conclusion

Shilpa’s rHA programme combines a yeast-fermentation process, animal-origin-free manufacturing inputs, patents in the United States and Europe, and Orion’s exclusive European therapeutic commercialization role. The key disclosed milestone is clinical progress: India and European Union Phase III starts are targeted for 2HFY27, not a stated product approval, launch or revenue contribution.

The next points to watch are whether Shilpa initiates both Phase III programmes and makes its planned European Medicines Agency dossier submission in 2HFY27, as well as whether it completes the United States pre-Investigational New Drug filing in FY27. Trial design, completion dates, regulatory outcomes and the value and timing of Orion milestone payments remain unresolved in the presentation.